Many 340B Disproportionate Share Hospitals Fail to Reinvest in Patient Care
'Most 340B disproportionate share hospitals have morphed into corporate profit machines, putting Wall Street-style growth ahead of patient care. Many hospitals that joined the program in 2016 and 2017 boosted their financial portfolios – while slashing the amount of free and discounted care they provided. This isn't just a betrayal of the program's purpose – but a betrayal of public trust,' said Mike Kapsa, Board Member, CARH.
In theory, DSH participation in the 340B program should enhance care for vulnerable patients. But the data tell a different story: 340B DSHs are reducing their commitment to uncompensated care, all while growing financial reserves and investments. The study found DSHs that joined 340B between 2016 and 2017 reduced their spending on free or reduced cost care by 22%, on average, while increasing financial investments by 89% in the five years following enrollment.
'We continue to see growth in 340B drug sales and questions around hospital use of these funds,' said Amanda Forys, Managing Partner, Magnolia Market Access. 'This study supports the same narrative – disproportionate share hospitals are not directing 340B revenue toward patient care. Policies that promote appropriate use of 340B funds are needed to make sure vulnerable patients benefit from these steep drug discounts.'
The analysis and report were completed by Magnolia Market Access, made possible through support from CARH. To access the full analysis, visit HERE and learn more about how non-profit DSHs are misusing 340B revenue and the importance of program oversight to ensure vulnerable patients benefit, not corporate interests.
About Magnolia Market Access: Magnolia Market Access provides tailored strategies and insights to pharmaceutical companies, device manufacturers, and trade associations to meet their market access, HEOR, and healthcare policy needs. Our experts provide 360-degree perspectives and analysis of our in-house and client-specific clinical and real-world data to shape policy, communicate value, secure reimbursement, and drive patient access. For more information, visit https://www.magnoliamarketaccess.com.
About CARH: Community Action for Responsible Hospitals (CARH) is a non-profit organization of patient-focused stakeholders including labor unions, faith leaders, healthcare providers, consumer advocates, and public interest groups. For more information, visit https://www.betterhospitalsnow.org
1 Established in 1992 under the Public Health Service Act, the 340B Drug Pricing Program is a federal program that provides discounts on outpatient prescription drugs to 'covered entities,' such as qualifying hospitals and clinics that treat a high number of low-income and uninsured individuals.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Key Points Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, achieving only 12.4% weight loss. Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no margin for competitive disruption. 10 stocks we like better than Eli Lilly › Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money faster than the Fed. But here's what the bulls aren't telling you: The company's next-generation oral weight-loss pill just delivered a reality check, and a scrappy competitor is positioning itself to steal the most lucrative slice of the $100 billion obesity treatment market. At today's premium valuation, that's a risk investors can't afford to ignore. The obesity empire strikes back Lilly's second-quarter numbers read like a growth investor's fantasy. Revenue surged 38% to $15.56 billion, with Mounjaro generating $5.2 billion (up 68%) and Zepbound delivering $3.38 billion (up 172% in the U.S. alone). The company raised full-year guidance to a range of $60 billion to $62 billion in revenue, with earnings per share expected between $21.75 and $23. That's a 61% jump in quarterly earnings to $6.31 per share, powered by an impressive 85% gross margin. The incretin drug portfolio now accounts for over half of Lilly's total revenue, a concentration that amplifies any competitive threat. The ATTAIN-1 trial results had already cast a shadow over these stellar financials. Orforglipron, Lilly's much-anticipated oral GLP-1 pill, delivered 12.4% weight loss at its highest dose, or about 27 pounds for the average patient. The stock dropped 14% on the news, and for good reason: Novo Nordisk's (NYSE: NVO) Wegovy achieves 14% to 15% weight loss with injections, while experimental oral competitors like Novo's CagriSema are targeting 20%. This underperformance matters financially: It narrows Lilly's addressable oral market, weakens its mass-market capture strategy, and hands ammunition to payers pushing for lower reimbursement rates. The Viking invasion nobody sees coming Here's why Viking Therapeutics (NASDAQ: VKTX) represents the only viable near-term threat with a real shot at breaching Lilly's obesity moat. VK-2735 isn't just another GLP-1 -- it's a dual GLP-1/GIP agonist attacking the market from two angles. The subcutaneous formulation, now in Phase 3, could launch as early as 2027. The oral version, currently in Phase 2, gives Viking a second shot at the convenience-seeking patient population that Lilly is struggling to capture with orforglipron. The Phase 2 numbers back up the threat. The subcutaneous version delivered 14.7% weight loss with significantly cleaner tolerability than current options -- 95% of gastrointestinal side effects were mild or moderate. The oral version's Phase 1 data showed something even more intriguing: Weight loss persisted six days after the last dose, suggesting durability that could become a marketing differentiator. Viking is also exploring monthly dosing that would revolutionize patient compliance. But here's the killer insight: VK-2735 is perfectly positioned to capture the patients that Lilly's retatrutide can't hold. While retatrutide might deliver blockbuster weight-loss numbers, its triple-agonist mechanism comes with tolerability trade-offs that could drive discontinuations. Viking's cleaner profile targets the population with a body mass index of 30 to 38 -- the most profitable recurring-revenue segment that generates decades of prescriptions. These aren't the sickest patients; they're the volume players who want results without harsh side effects. Timing turns this from a threat to a crisis. VK-2735's subcutaneous version could launch around 2027, with an oral version potentially following in 2028 -- precisely when orforglipron would be struggling to gain traction with inferior efficacy. If a major pharma partner like Pfizer or Amgen steps in, the launch scale could rival Lilly's overnight. The valuation trap At 29 times forward earnings, Lilly's market cap bakes in an uninterrupted march toward obesity dominance. VK-2735's entry could disrupt that march years before the Street expects it. The market is essentially betting that Mounjaro and Zepbound maintain trajectory, orforglipron somehow overcomes its efficacy gap, and retatrutide delivers without causing mass patient discontinuations. Those are three separate high-stakes bets, all priced for perfection. With these treatments now accounting for over half of its revenue, any market share loss hits twice as hard. Each percentage point Viking captures doesn't just reduce growth -- it challenges the entire premium multiple. Lilly bulls might argue the company's deep pipeline justifies today's valuation, and the 38% revenue growth proves this machine knows how to monetize innovation. But the orforglipron disappointment reveals that even Lilly can't guarantee every pipeline bet pays off. With Novo already commanding a significant share and Viking developing a dual-formulation strategy that offers more flexibility than anything in Lilly's pipeline, the duopoly's days could be numbered. At today's premium valuation, there's minimal margin for error and zero room for surprise competition. For investors, the smartest move might be taking some profits on Lilly's incredible run and watching Viking's Phase 2 oral results in the second half of 2025 from the safety of the sidelines -- that's when the real disruption story might start to unfold. Should you buy stock in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 George Budwell has positions in Pfizer and Viking Therapeutics and has the following options: long January 2026 $55 calls on Viking Therapeutics, long January 2026 $60 calls on Viking Therapeutics, and long January 2027 $60 calls on Viking Therapeutics. The Motley Fool has positions in and recommends Amgen and Pfizer. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet. was originally published by The Motley Fool Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
3 hours ago
- Yahoo
Axon's Q2 Earnings Call: Our Top 5 Analyst Questions
Axon's second quarter drew strong positive market reaction, reflecting the company's ongoing ability to exceed Wall Street's expectations. Management credited the company's robust performance to accelerating adoption of new software solutions, as well as deeper customer relationships across state, local, and international markets. CEO Patrick Smith highlighted rapid uptake of products like Draft One and TASER 10, noting that 'demand for new technology from our customers is accelerating, and it's outpacing even my most optimistic expectations.' The quarter was also characterized by a record-breaking contract in the state and local segment and notable contributions from the corrections and enterprise verticals. Is now the time to buy AXON? Find out in our full research report (it's free). Axon (AXON) Q2 CY2025 Highlights: Revenue: $668.5 million vs analyst estimates of $641 million (32.8% year-on-year growth, 4.3% beat) Adjusted EPS: $2.12 vs analyst estimates of $1.46 (45% beat) Adjusted EBITDA: $171.6 million vs analyst estimates of $161.3 million (25.7% margin, 6.4% beat) The company lifted its revenue guidance for the full year to $2.69 billion at the midpoint from $2.65 billion, a 1.5% increase EBITDA guidance for the full year is $675 million at the midpoint, in line with analyst expectations Operating Margin: -0.2%, down from 6.7% in the same quarter last year Annual Recurring Revenue: $1.18 billion vs analyst estimates of $1.14 billion (39.2% year-on-year growth, 3.7% beat) Market Capitalization: $60.34 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Our Top 5 Analyst Questions From Axon's Q2 Earnings Call Keith Housum (Northcoast Research) asked about which products are driving enterprise market traction. Chief Operating Officer Joshua Isner highlighted broad product suite adoption, noting both body cameras and AI solutions are seeing strong interest. Andrew Sherman (TD Cowen) inquired about accelerating demand for AI Era Plan products. Isner confirmed demand is 'absolutely accelerating,' crediting customer feedback and visible time savings as key adoption drivers. William Power (Baird) sought more detail on counter-drone growth and its law enforcement versus enterprise mix. CEO Patrick Smith described Dedrone as a 'market leader,' with broadening demand across both sectors and rapid iteration to address evolving threats. Meta Marshall (Morgan Stanley) questioned how Axon overcomes adoption hurdles for new AI products. Isner explained that hands-on user feedback and pilot programs are most effective, with customers quickly seeing practical value. Alyssa Shreves (Barclays) asked if international outperformance will shift segment mix. Isner replied that while international will grow, the U.S. remains strong, so mix changes may be gradual rather than rapid. Catalysts in Upcoming Quarters Looking ahead, our analysts will focus on (1) the pace of customer upgrades from basic to premium and AI-enabled product bundles, (2) Axon's ability to manage tariff-driven cost pressures while protecting margins, and (3) execution on large international and enterprise contracts. Progress in R&D hiring and new product launches will also be essential indicators of Axon's long-term trajectory. Axon currently trades at $772, up from $742.75 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it's free). High-Quality Stocks for All Market Conditions When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that's already erased most losses. Don't let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 hours ago
- Yahoo
3 reasons the Fed hasn't cut rates yet this year
Wall Street has priced in a 94.2% probability of the Federal Reserve cutting interest rates in September. JPMorgan Asset Management's fixed income portfolio manager, Kelsey Berro, joins Yahoo Finance Senior Reporter Allie Canal on Market Domination to explain the three reasons the Fed still hasn't cut rates this year despite macro conditions being comparable to last year's. To watch more expert insights and analysis on the latest market action, check out more Market Domination. Related videos Mortgage broker reveals $112,000 home loan mistake: 'Costing you a bomb' ATO tax return warning to millions over common car deduction: 'You can't' Work from home shift for millions of Aussies as 'clear link' with salaries revealed: '$300,000 or more' ATO superannuation warning for 200,000 Aussies ahead of looming deadline: 'On the hook for penalties' Sign in to access your portfolio
